3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Mar. 9];6(6):s78. Available from: https://skin.dermsquared.com/skin/article/view/1836